Interestingly, reanalysis of RNA-seq data from a previous PyMT GEMM study revealed no difference in Smarcd1 expression between matched primary and metastatic tumors across several genetic backgrounds. The gene discussed is SMARCD1; the disease is metastatic neoplasm.